A study evaluating infections in patients receiving Ibrutinib for treatment of lymphoma.

Trial Profile

A study evaluating infections in patients receiving Ibrutinib for treatment of lymphoma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Diffuse large B cell lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Oct 2017 New trial record
    • 08 Oct 2017 Results presented at the IDWeek 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top